Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR TTF_AC vs CRT · elderly people with newly diagnosed glioblastoma Interventions: one treatment option Comparison: an alternative… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR IRI_BEV_RT vs CRT · elderly people with newly diagnosed glioblastoma Interventions: one treatment option Comparison: an alternative… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR RT vs supportive care only · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hypofractionated RT vs standard RT (60Gy/30 fractions) · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 1 study · 61 participants | Ungraded |
Intervention NR TMZ vs RT · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 1 study · 373 participants | Moderate |
Intervention NR RT40 (4 RCTs; 930 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40);… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | HR 0.44 [0.25, 0.77] | 4 studies · 40 participants | Low |
Intervention NR CRT vs RT · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 1 study · 562 participants | Moderate |
Intervention NR BEV_CRT vs CRT · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 1 study · 73 participants | Moderate |
Intervention NR BEV_RT vs RT · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 1 study · 75 participants | Low |
Intervention NR RIN_CRT vs CRT · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 1 study · 174 participants | Ungraded |
Intervention NR TTF_AC vs AC · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 1 study · 134 participants | Ungraded |
Intervention NR IRI_BEV_RT vs CRT · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 1 study · 34 participants | Ungraded |
Intervention NR TMZ (3 RCTs, 538 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40);… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | HR 0.42 [0.25, 0.71] | 3 studies · 538 participants | Low |
Intervention NR CRT (2 RCTs; 635 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40);… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | HR 0.3 [0.17, 0.53] | 2 studies · 635 participants | Ungraded |
Intervention NR BEV_CRT (1 RCT; 73 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40);… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | HR 0.25 [0.11, 0.54] | 1 study · 73 participants | Ungraded |
Intervention NR RT 40 (4 RCTs; 930 participants) · elderly people with newly diagnosed glioblastoma Interventions: chemoradiotherapy (CRT); chemoradiotherapy plus… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | 4 studies · 40 participants | Ungraded |
Intervention NR BEV_RT (1 RCT; 75 participants) · elderly people with newly diagnosed glioblastoma Interventions: chemoradiotherapy (CRT); chemoradiotherapy plus… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | HR 1.08 [0.66, 1.78] | 1 study · 75 participants | Low |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone QoL · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | 1 study · 245 participants | Very low |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone Improvement of ascites‐related symptoms · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone Adverse events · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | 1 study · 157 participants | Very low |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone Participant satisfaction · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone Caregiver satisfaction · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone Cost‐effectiveness · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
GnRH agonist plus chemotherapy vs chemotherapy alone Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 1.6 [1.14, 2.24] | 5 studies · 460 participants | Low |
GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | no estimate extracted | 0 participants | Ungraded |
GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 3 [0.13, 70.3] | 1 study · 50 participants | Very low |
GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | no estimate extracted | 0 participants | Ungraded |
GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone Adverse events · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | no estimate extracted | 0 participants | Ungraded |
GnRH agonist plus chemotherapy vs chemotherapy alone Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 1.08 [0.95, 1.22] | 8 studies · 869 participants | Low |
GnRH agonist plus chemotherapy vs chemotherapy alone Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 0.44 [0.31, 0.61] | 4 studies · 780 participants | Moderate |
GnRH agonist plus chemotherapy vs chemotherapy alone Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 1.59 [0.93, 2.7] | 7 studies · 703 participants | Low |
GnRH agonist plus chemotherapy vs chemotherapy alone Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 2.47 [1.43, 4.26] | 2 studies · 95 participants | Low |
GnRH agonist plus chemotherapy vs chemotherapy alone Adverse effects: hot flush · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 1.49 [0.16, 13.6] | 4 studies · 731 participants | Very low |
GnRH agonist plus chemotherapy vs chemotherapy alone Adverse effects: vaginal dryness · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 1.18 [0.68, 2.04] | 2 studies · 488 participants | Moderate |
GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 1 [0.76, 1.32] | 1 study · 50 participants | Very low |
GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature… (2019) · Cochrane | RR 0.93 [0.56, 1.55] | 1 study · 50 participants | Very low |
Ovarian stimulating drugs in subfertile women vs subfertile women not treated or versus general population Risk of invasive ovarian cancer in subfertile women exposed to ovarian stimulating drug vs unexposed women (summary of cohort studies suggesting increased risk) · for subfertile women Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility (2019) · Cochrane | no estimate extracted | 4 studies · 194583 participants | Very low |
Ovarian stimulating drugs in subfertile women vs subfertile women not treated or versus general population Risk of invasive ovarian cancer in subfertile women exposed to ovarian stimulating drugs vs unexposed women (summary of case‐control studies suggesting increased risk) · for subfertile women Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility (2019) · Cochrane | no estimate extracted | 2 studies · 35 participants | Very low |
Ovarian stimulating drugs in subfertile women vs subfertile women not treated or versus general population Risk of borderline ovarian tumours in subfertile women exposed to ovarian stimulating drugs vs unexposed women (summary of cohort studies suggesting increased risk) · for subfertile women Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility (2019) · Cochrane | no estimate extracted | 5 studies · 1381732 participants | Very low |
Ovarian stimulating drugs in subfertile women vs subfertile women not treated or versus general population Risk of borderline ovarian cancer in subfertile women exposed to ovarian stimulating drugs vs unexposed women (summary of case‐control studies suggesting an increase) · for subfertile women Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility (2019) · Cochrane | no estimate extracted | 2 studies · 28 participants | Very low |
Outpatients vs inpatients ‐ adults Treatment failure · Adult patients with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | RR 1.23 [0.82, 1.85] | 6 studies · 628 participants | Moderate |
Outpatients vs inpatients ‐ children Adverse drug reactions · Children with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | RR 1.9 [0.61, 5.98] | 2 studies · 156 participants | Low |
Outpatients vs inpatients ‐ children Duration of neutropaenia (days) · Children with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | no estimate extracted | 2 studies · 268 participants | Moderate |
Outpatients vs inpatients ‐ children Duration of hospitalisation (days) · Children with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | no estimate extracted | 1 study · 119 participants | Low |
Outpatients vs inpatients ‐ children Duration of antimicrobial treatment (days) · Children with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | no estimate extracted | 3 studies · 305 participants | Low |
Outpatients vs inpatients ‐ adults Mortality · Adult patients with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | RR 1.04 [0.29, 3.71] | 6 studies · 628 participants | Moderate |
Outpatients vs inpatients ‐ adults Duration of fever (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | no estimate extracted | 1 study · 169 participants | Low |
Outpatients vs inpatients ‐ adults Adverse drugs reactions · Adult patients with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | RR 8.39 [0.38, 187.15] | 3 studies · 375 participants | Low |
Outpatients vs inpatients ‐ adults Duration of neutropaenia (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | no estimate extracted | 1 study · 169 participants | Low |
Outpatients vs inpatients ‐ adults Duration of hospitalisation (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane | no estimate extracted | 3 studies · 251 participants | Low |